Jupiter Asset Management Ltd. Has $9.10 Million Stake in Aurinia Pharmaceuticals Inc $AUPH

Jupiter Asset Management Ltd. reduced its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 11.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 823,579 shares of the biotechnology company’s stock after selling 110,283 shares during the period. Jupiter Asset Management Ltd. owned 0.62% of Aurinia Pharmaceuticals worth $9,101,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in shares of Aurinia Pharmaceuticals by 21.7% in the third quarter. JPMorgan Chase & Co. now owns 533,290 shares of the biotechnology company’s stock worth $5,893,000 after acquiring an additional 94,941 shares during the period. Baader Bank Aktiengesellschaft bought a new position in Aurinia Pharmaceuticals during the 3rd quarter worth approximately $344,000. Navellier & Associates Inc. bought a new position in Aurinia Pharmaceuticals during the 3rd quarter worth approximately $926,000. State of Wyoming lifted its position in shares of Aurinia Pharmaceuticals by 33.2% in the 3rd quarter. State of Wyoming now owns 37,702 shares of the biotechnology company’s stock worth $417,000 after purchasing an additional 9,396 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Aurinia Pharmaceuticals by 6.7% in the 3rd quarter. Principal Financial Group Inc. now owns 80,740 shares of the biotechnology company’s stock worth $892,000 after purchasing an additional 5,074 shares during the period. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $14.40 on Friday. Aurinia Pharmaceuticals Inc has a one year low of $6.55 and a one year high of $16.54. The company has a market cap of $1.90 billion, a PE ratio of 25.71 and a beta of 1.50. The stock has a 50-day moving average of $15.12 and a 200-day moving average of $13.80. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.76 and a quick ratio of 5.17.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the company from $10.00 to $21.00 in a research report on Friday, November 7th. Leerink Partners downgraded Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals has an average rating of “Hold” and an average price target of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.